Abl Bio Inc.

Legochem Biosciences, Inc.

I-mab Biopharma US Limited

I-mab Biopharma Co., Ltd.

Jiseon Yoo

Bora Lee

Yangsoon Lee

Kyungjin Park

Donghoon Yeom

Sang Hoon Lee

Juhee Kim

Yeunju Kim

Byungje Sung

Hyejin Chung

Eunsil Sung

Jinhyung Ahn

Daehae Song

Yong-Gyu Son

Jaehyun Eom

Jaeho Jung

Jinwon Jung

Minji Park

Eunjung Kim

Dongin Kim

Lei Fang

Yong Zu Kim

Ho Young Song

Ju Young Lee

Jeiwook Chae

Sung Min Kim

Hyoung Rae Kim

Kyung Eun Park

Wenqing Jiang

Eunyoung Park

Youngdon Pak

Dae Hyuck Kang

Kyeongsu Park

Chang Sun Lee

Yun-Hee Park

Ji Hye Oh

Youngkwang Kim

Seawon Ahn

Hyeun Joung Lee

Sungwon An

Weon-Kyoo You

Hyun Min Ryu

Hyoju Choi

JinWon Jung

Weonkyoo You

Mikyung Chang

Ju Yuel Baek

Jaehyoung Jeon

Young-Jae Yang

Junhyun Jeong

Yoseob Lee

Nara Han

Ji-Na You

Youngeun Hong

Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

Anti-BCMA antibody and use thereof

The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

Growing community of inventors

Seongnam-si, South Korea

Jiseon Yoo